Viking Therapeutics Inc
VKTX35.190USD
+1.240+3.65%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.96BMarket Cap
LossP/E TTM
More Details of Viking Therapeutics Inc Company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Viking Therapeutics Inc Info
Ticker SymbolVKTX
Company nameViking Therapeutics Inc
IPO dateApr 29, 2015
CEOLian (Brian W)
Number of employees36
Security typeOrdinary Share
Fiscal year-endApr 29
Address9920 Pacific Heights Blvd, Suite 350
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18587044660
Websitehttps://vikingtherapeutics.com/
Ticker SymbolVKTX
IPO dateApr 29, 2015
CEOLian (Brian W)
Company Executives of Viking Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Mr. J. Matthew Singleton, CPA
Mr. J. Matthew Singleton, CPA
Independent Director
Independent Director
--
--
Dr. Brian W. Lian, Ph.D.
Dr. Brian W. Lian, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.82%
Fidelity Management & Research Company LLC
4.36%
State Street Investment Management (US)
3.99%
BlackRock Institutional Trust Company, N.A.
3.90%
Two Sigma Investments, LP
3.22%
Other
75.69%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.82%
Fidelity Management & Research Company LLC
4.36%
State Street Investment Management (US)
3.99%
BlackRock Institutional Trust Company, N.A.
3.90%
Two Sigma Investments, LP
3.22%
Other
75.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.68%
Investment Advisor/Hedge Fund
14.30%
Hedge Fund
10.18%
Research Firm
5.09%
Individual Investor
2.17%
Sovereign Wealth Fund
1.56%
Pension Fund
0.62%
Bank and Trust
0.50%
Private Equity
0.09%
Other
31.79%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
900
75.89M
67.14%
-19.31M
2025Q2
873
80.91M
71.95%
-19.10M
2025Q1
881
81.93M
72.95%
-19.61M
2024Q4
837
90.73M
82.19%
-16.87M
2024Q3
781
90.59M
82.61%
-15.25M
2024Q2
701
89.78M
82.34%
-10.20M
2024Q1
634
89.55M
82.55%
-7.02M
2023Q4
464
85.12M
85.96%
-16.14M
2023Q3
442
85.70M
86.63%
-10.01M
2023Q2
426
82.52M
83.46%
-982.32K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
10.14M
9.02%
-3.81K
-0.04%
Jun 30, 2025
Fidelity Management & Research Company LLC
7.63M
6.78%
-2.60M
-25.41%
Jun 30, 2025
State Street Investment Management (US)
3.78M
3.36%
-279.73K
-6.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.31M
3.83%
-564.54K
-11.59%
Jun 30, 2025
Two Sigma Investments, LP
2.41M
2.14%
+2.35M
+4488.87%
Jun 30, 2025
JP Morgan Asset Management
2.51M
2.24%
-188.76K
-6.99%
Jun 30, 2025
Susquehanna International Group, LLP
2.07M
1.84%
+389.85K
+23.25%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
1.66M
1.48%
+580.22K
+53.52%
Jun 30, 2025
Lian (Brian)
1.94M
1.73%
+21.44K
+1.12%
Jul 03, 2025
Citadel Advisors LLC
872.98K
0.78%
-778.12K
-47.13%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
6.38%
State Street SPDR S&P Biotech ETF
2.01%
Formidable ETF
1.84%
ALPS Medical Breakthroughs ETF
1.81%
WisdomTree BioRevolution Fund
1.2%
Direxion Daily S&P Biotech Bull 3X Shares
1.14%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Tema Heart & Health ETF
0.53%
Pacer WealthShield ETF
0.29%
Inspire Small/Mid Cap ESG ETF
0.29%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion6.38%
State Street SPDR S&P Biotech ETF
Proportion2.01%
Formidable ETF
Proportion1.84%
ALPS Medical Breakthroughs ETF
Proportion1.81%
WisdomTree BioRevolution Fund
Proportion1.2%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.14%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.9%
Tema Heart & Health ETF
Proportion0.53%
Pacer WealthShield ETF
Proportion0.29%
Inspire Small/Mid Cap ESG ETF
Proportion0.29%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Viking Therapeutics Inc?
The top five shareholders of Viking Therapeutics Inc are:
The Vanguard Group, Inc. holds 10.14M shares, accounting for 9.02% of the total shares.
Fidelity Management & Research Company LLC holds 7.63M shares, accounting for 6.78% of the total shares.
State Street Investment Management (US) holds 3.78M shares, accounting for 3.36% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.31M shares, accounting for 3.83% of the total shares.
Two Sigma Investments, LP holds 2.41M shares, accounting for 2.14% of the total shares.
The Vanguard Group, Inc. holds 10.14M shares, accounting for 9.02% of the total shares.
Fidelity Management & Research Company LLC holds 7.63M shares, accounting for 6.78% of the total shares.
State Street Investment Management (US) holds 3.78M shares, accounting for 3.36% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.31M shares, accounting for 3.83% of the total shares.
Two Sigma Investments, LP holds 2.41M shares, accounting for 2.14% of the total shares.
What are the top three shareholder types of Viking Therapeutics Inc?
The top three shareholder types of Viking Therapeutics Inc are:
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
State Street Investment Management (US)
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
State Street Investment Management (US)
How many institutions hold shares of Viking Therapeutics Inc (VKTX)?
As of 2025Q3, 900 institutions hold shares of Viking Therapeutics Inc, with a combined market value of approximately 75.89M, accounting for 67.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.81%.
What is the biggest source of revenue for Viking Therapeutics Inc?
In --, the -- business generated the highest revenue for Viking Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
